Details of the Drug
General Information of Drug (ID: DM0UBI9)
Drug Name |
N,N-diethyl-2-(1H-indol-3-yl)ethanamine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Diethyltryptamine; N,N-Diethyltryptamine; 61-51-8; N,N-Diethyl-2-(1H-indol-3-yl)ethanamine; 3-(2-Diethylaminoethyl)indole; UNII-916E8V4S2V; INDOLE, 3-(2-(DIETHYLAMINO)ETHYL)-; BRN 0153320; D.E.T.; CHEMBL142936; DEA No. 7434; 916E8V4S2V; 1H-Indole-3-ethanamine, N,N-diethyl-; AC1L1LS6; Oprea1_105894; 5-22-10-00050 (Beilstein Handbook Reference); SCHEMBL517713; DTXSID9052763; CTK5B3364; LSSUMOWDTKZHHT-UHFFFAOYSA-N; ZINC1999162; BDBM50094676; STK368075; AKOS005444987; 1H-Indole-3-ethanamine,N,N-diethyl-; 63938-63-6 (mono-hydrochloride)
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 216.32 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.3 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 5 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||